ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0133

Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus

Erica Rosen1 and Megan Krause2, 1University of Kansas, Kansas City, MO, 2University of Kansas, Kansas City, KS

Meeting: ACR Convergence 2021

Keywords: Cancer, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of cervical cancer in the general public to be 7.5/100,000. The incidence has been reported to be significantly higher in females with SLE. Prior studies suggested that women with SLE have lower rates of undergoing timely cervical cancer screenings compared to the general population. The American Cancer Society recommends screening women with SLE at age 21 or 1 year after sexual activity, whichever comes first, with annual pap testing for patients age < 30 and a yearly pap with HPV co-testing if >30. For the general population of women ages 21-65 pap testing every 3 years is recommended for patients < 30 and if >30 cytology is recommended every 3 years or cytology with HPV co-testing every 5 years. This study aimed to determine the rate of cervical cancer screening and incidence of cervical cancer in women with SLE at our single academic institution.

Methods: A retrospective chart review was conducted at a single tertiary center. Females were included who had the diagnosis of SLE by ICD9/10 codes, had three or more rheumatology visits, and two or more visits with family medicine, internal medicine or OBGYN between the years of 2004-2020. Eligible patients were between 21-65 years of age. The search also included the number of pap smear procedure codes per patient. The rate of cervical cancer screening was estimated for each patient by finding the time difference between the first office visit and last office visit divided by the number of pap smears. A search was also conducted to identify patients who had hysterectomy and only time prior to hysterectomy was included when determining the screening rate. A search was also conducted to identify the incidence of cervical cancer.

Results: 145 patients were identified. 21 patients were found to have had a hysterectomy at some point during the time period and only the time prior to hysterectomy was included. The average time between cervical cancer screenings was found to be 55 months or 4.5 years. Furthermore, increasing age directly correlated with a decrease in screening. The average time between cervical cancer screening for women ages 21-29 was 27 months, women ages 30-39 was 53 months, women ages 40-49 was 50 months, women ages 50-59 was 63 months and women ages >60 was 80 months. Additionally, 4 patients had developed cervical cancer resulting in an incidence of 2.7%. A root cause analysis was preformed to identify causes for decreased cervical cancer screenings.

Conclusion: This chart review identified inadequate cervical cancer screening in women with SLE at this tertiary center. The time between screenings decreased with increasing age. Further research is needed to determine an appropriate screening interval for these patients to avoid unnecessary invasive procedures and increased costs. Future steps are to collaborate with the OBGYN department to provide an interdisciplinary approach in determining appropriate screening intervals and an intervention to improve the overall cervical cancer screening rate in this patient population.

Cause and Effect Diagram


Disclosures: E. Rosen, None; M. Krause, None.

To cite this abstract in AMA style:

Rosen E, Krause M. Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/cervical-cancer-screening-rate-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cervical-cancer-screening-rate-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology